rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TOVX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Theriva Biologics: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceTOVX
      Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results
      Nov 12Yahoo FinanceTOVX
      Theriva sells antibiotic-degrading enzyme portfolio to Biossil
      Nov 2Investing.comTOVX
      Theriva publishes VCN-01 pancreatic cancer trial data in journal
      Sep 30Investing.comTOVX
      Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

      - Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer - - Data are consistent with an immune mediated mechanism of action for VCN-01 that may enhance the antitumor effects of a range of coadministered pancreatic cancer therapies - - The feasibility of administering more frequent repeated VCN-01 doses to potentially improve clinical outcomes in metastatic pancreat

      Sep 30Yahoo FinanceTOVX

      This is the newest page. Registered accounts read further back.